Instil Bio (TIL) Shares are Fairly Valued Till Phase 2 Dose Results - Citizens

Citizens analyst Reni Benjamin reiterated a Market Perform rating on Instil Bio Inc (NASDAQ: TIL).

The analyst commented, "We maintain our Market Perform rating on Instil Bio based on a cash/share and platform value analysis. Recently, Instil reported 3Q25 financial results and clinical trial progress, including an announcement that, in October, the company had dosed the first patient in its U.S.-based Phase 1B/2 doseescalation bridging study. The company also highlighted partner ImmuneOnco’s (NC) presentation of ‘2510 monotherapy in relapsed/refractory NSCLC. While the company’s trials are progressing on schedule, and promising updated NSCLC data were presented, we remain on the sidelines and see shares as fairly valued until we can evaluate a more robust set of results at the recommended Phase 2 dose."

For an analyst ratings summary and ratings history on Instil Bio Inc click here. For more ratings news on Instil Bio Inc click here.

Shares of Instil Bio Inc closed at $12.77 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'